RxDoctor Payments Data

Jacqueline Brewer

Adult Health · Sterling Heights, MINPI 1619466216

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $83,467 of the $138,466 with a category attached, or 60.3%. 7 manufacturers reported payments, led by United Therapeutics Corporation at 58.3% of the total. Among adult health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$138,466in general payments, 2019–2025

Across 348 payments — averaging $397.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$81K
  • Actelion Pharmaceuticals US, Inc.$39K
  • Johnson & Johnson$16K
  • Merck$2K
  • Bayer$45
  • Verona Pharma, Inc.$26
  • plus $16 from 1 others

What the payments were for

  • Consulting fees$25,26018%
  • Speaking & faculty fees$83,46760%
  • Travel & lodging$22,32116%
  • Food & beverage$7,3765%
  • Education$410%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,466 in reported general payments places this provider in the 95th percentile of 527 adult health providers in Michigan.

See all adult health providers in Michigan

Medicare billing

Part B allowed, 2024
$7,420
Medicare patients
44
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil120$2,889,476
OpsumitMacitentan164$2,094,550
AdempasRiociguat65$907,046
Orenitram ErTreprostinil Diolamine93$898,890
Ambrisentan85$225,950
OpsynviMacitentan/Tadalafil13$164,423
Tadalafil173$95,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$91,854
XareltoRivaroxaban19$15,219
Sildenafil Citrate38$13,468
Breo ElliptaFluticasone/Vilanterol16$13,005
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$6,029
Albuterol Sulfate HfaAlbuterol Sulfate42$1,943
Bumetanide58$1,477
Azelastine Hcl15$676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Opsynvi$39,142$2,258,972177 claims
BayerAdempas$45$907,04665 claims
Johnson & JohnsonXarelto$16,314$15,21919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 adult health providers in Michigan.

Other adult health in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →